The SSRI discontinuation syndrome

Journal of Psychopharmacology

Volumn 12, Issue 3, 1998, Pages 305-313

  Haddad, Peter ^a  

^a TRAFFORD GENERAL HOSPITAL   (United Kingdom)

Author keywords

Adverse drug reaction; Diagnostic criteria; Review; Serotonin uptake inhibitors; Substance withdrawal syndrome; Withdrawal

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGITATION; AMNESIA; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; DIARRHEA; FEMALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LETHARGY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SWEATING; TREMOR; VERTIGO; WITHDRAWAL SYNDROME;

EID: 0031794340     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119801200311     Document Type: Review

References (66)

1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington DC
2. Australian Adverse Drug Reactions Advisory Committee (1996) SSRIs and withdrawal syndrome. Aust Adv Drug React Bull 15: 3
3. Barr L C, Goodman W K, Price L H (1994) Physical symptoms associated with paroxetine discontinuation. Am J Psychiat 151: 289
4. Berlin C S (1996) Fluoxetine withdrawal symptoms. J Clin Psychiat 57: 93-94
5. Bertilsson L, Dahl M L, Sjöqvist F, Åberg-Wistedt A, Humble M, Johansson I, Lundqvist E, Ingelman-Sundberg M (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341: 63
6. Bhaumik S, Wildgust H J (1996) Letter to the editor. Human Psychopharmac 11: 337-338
7. Bialos D, Giller E, Jatlow P, Docherty J, Harkness K (1982) Recurrence of depression after discontinuation of amitriptyline. Am J Psychiat 139: 325-329
8. Black D W, Wesner R, Gabel J (1993) The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiat 54: 146-149
9. Black K, Shea C, Dursun S, Kutcher S (1997) Selective serotonin reuptake inhibitor (SSRI) withdrawal syndrome: proposed diagnostic criteria (abstract). J Psychopharmac 11 (Suppl.3): A31, poster 121
10. Bloch M, Stager S V, Braun A R, Rubinow D R (1995) Severe psychiatric symptoms associated with paroxetine withdrawal. Lancet 346: 57
11. Blomgren S L, Krebs W, Wilson M, Ascroft R, Fave M, Rosenbaum J (1997) SSRI dose interruption study: interim data (abstract). American Psychiatric Association, 150th Annual Meeting, San Diego, CA, May 17-22 1997. New Research Abstracts: NR 188. American Psychiatric Association, Washington DC
12. British National Formulary (1998) The Pharmaceutical Press, London
13. Brosen K, Gram L F (1989) Clinical significance of the sparteine/ debrisoquine oxidation polymorphism. Eur J Clin Pharmac 36: 537-547
14. Coccaro E F (1989) Central serotonin and impulsive aggression. Br J Psychiat 155 (Suppl. 8): 52-62
15. Committee on Safety of Medicines (1993) Dystonias and withdrawal symptoms with paroxetine (seroxat). Curr Prob Pharmacovigilance 19: 1
16. Coupland N J, Bell C J, Potokar J P (1996) Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmac 16: 356-362
17. Dahl M L, Olhager E, Ahlner J (1997) Paroxetine withdrawal syndrome in a neonate. Br J Psychiat 171: 391-392
18. Debattista C, Schatzberg A F (1995) Physical symptoms associated with paroxetine withdrawal. Am J Psychiat 152: 1235-1236
19. Delgado P L, Charney D S, Price L H, Aghajanian G K, Landi H, Nheninger G R (1990) Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Archs Gen Psychiat 47: 411-418
20. Diamond B I, Borison R L, Katz R et al. (1989) Rebound reactions due to clomipramine. Psychopharmac Bull 255: 209-212
21. Dilsaver S C, Greden J F, Snider R M (1987) Antidepressant withdrawal syndromes: phenomenology and physiology. Int Clin Psychopharmac 2: 1-19
22. Dominguez R A, Goodnick P J (1996) Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 15: 778-780
23. Einbinder E (1995) Fluoxetine withdrawal? Am J Psychiat 152: 1253
24. Ellison J M (1993) SSRI withdrawal buzz. Am J Psychiat 55: 544-545
25. Farah A, Lauer T (1996) Possible venlafaxine withdrawal syndrome. Am J Psychiat 153: 576
26. Fava G A, Grandi S (1995) Withdrawal syndromes after paroxetine and sertraline discontinuation. J Clin Psychopharmac 15: 374-375
27. Feiger A D, Bielski R D, Bremmer J, Heiser J, Trivedi M, Wilcox C S (1996) Efficacy of nefazodone in continuation treatment of depression. Psychopharmac Bull 32: 444
28. Frost L, Lal S (1995) Shock-like sensations after discontinuation of selective serotonin reuptake inhibitor. Am J Psychiat 152: 810
29. Gardos G, Cole J O, Tarsy D (1978) Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiat 135: 1321-1324
30. Geller B, Cooper T B, Carr L G (1987) Prospective study of scheduled withdrawal from nortriptyline in children and adolescents. J Clin Psychopharmac 7: 252-254
31. Jacobs B L, Fornal C A (1953) 5-HT and motor control: a hypothesis. Trends Neurosci 16: 346-352
32. Johnson A M (1993) The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals. In Feighner J P, Boyer W F (eds), Selective serotonin re-uptake inhibitors. John Wiley, Chichester
33. Kent L S W, Laidlaw J D D (1995) Suspected congenital sertraline dependence. Br J Psychiat 167: 412-413
34. Keuthen N J, Cyr P, Ricciardi J A, Minichiello W E, Battolph M L, Jenike M A (1994) Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmac 14: 206-207
35. Keyser D L, Rodnitzky R L (1991) Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Archs Int Med 151: 794-796
36. Koopowitz L F, Berk M (1995) Paroxetine induced withdrawal effects. Hum Psychopharmac 10: 147-148
37. Kramer J C, Klein D F, Fink M (1961) Withdrawal symptoms following discontinuation of imipramine therapy. Am J Psychiat 118: 549-550
38. Law W, Petti T A, Kazadin A (1981) Withdrawal symptoms after graduated cessation of imipramine in children. Am J Psychiat 118: 647-650
39. Lejoyeux M, Ades J, Mourad I, Solomon J, Dilsaver S (1996) Anti-depressant withdrawal syndrome. CNS Drugs 5: 278-292
40. Louie A K, Lannon R A, Kirsch M A, Lewis T B (1996) Venlafaxine withdrawal reactions. Am J Psychiat 153: 1652
41. Mallya G, White K, Gunderson C (1993) Is there a serotonergic withdrawal syndrome. Biol Psychiat 33: 849-855
42. Mander A J, Loudon J B (1988) Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet 339: 15-17
43. Mann A M, MacPherson A S (1959) Clinical experience with imipramine (G22355) in the treatment of depression. Can Psychiat Ass J 4: 38-47
44. Meyer U A, Zanger U M, Grant D, Blum M (1990) Genetic polymorphisms of drug metabolism. Adv Drug Res 19: 197-241
45. Michelson D, Onawala R, Beasley M (1997) Abrupt discontinuation of fluoxetine: a randomised placebo-controlled study (abstract). American Psychiatric Association, 150th Annual Meeting, San Diego, CA, May 17-22 1997. New Research Abstracts: NR200. American Psychiatric Association, Washington DC
46. Oehrberg S, Christiansen P E, Behnke K, Borup A L, Severin B, Soegaard J, Calberg H, Juitge R, Ohrstrom J K, Manniche P M (1995) Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychiat 167: 374-379
47. Otani K, Tanaka O, Kaneko S et al. (1994) Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmac 9: 131-133
48. Pacheco L, Malo P, Aragues E, Etxebeste M (1996) More cases of paroxetine withdrawal syndrome. Br J Psychiat 169: 384
49. Page R C (1997) How to wean a patient off corticosteroids. Prescribes' J 37: 11-16
50. Philips S D (1995) A possible paroxetine withdrawal syndrome. Am J Psychiat 152: 645-346
51. Preskorn S H (1996) Clinical pharmacology of selective serotonin reuptake inhibitors, 1st edn. Professional Communications. Inc., Caddo, p. 118
52. Price J S, Waller P C, Wood S M, Mackay A V P (1996) A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors, including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmac 42: 757-763
53. Priest R G, Vize C, Roberts A, Tylee A (1996) Lay people's attitudes to treatment of depression: result of opinion poll for Defeat Depression Campaign just before its launch. BMJ 313: 858-859
54. Reeves R R, Pinkofsky H B (1996) Lhermitte's sign in paroxetine withdrawal. J Clin Psychopharmac 16: 411-412
55. Rosenblatt J E, Rosenblatt N C (1996) Paroxetine withdrawal after slow dosage taper. Curr Affect Illness 15: 8-9
56. Rosenstock H A (1996) Sertraline withdrawal in two brothers: a case report. Int Clin Psychopharmac 11: 58-59
57. Rothchild A J (1995) Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiat 152: 1514-1516
58. Routledge P A, Bialas M C (1997) Adverse reactions to drug withdrawal. Adv Drug React Bull 187: 711-714
59. Simpson C J (1984) Doctors' and nurses' use of the word 'confused'. Br J Psychiat 145: 441-443
60. Spencer M J (1993) Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 92: 721-722
61. Stoukides J A, Stoukides C A (1991) Extrapyramidal symptoms upon discontinuation of fluoxetine. Am J Psychiat 148: 1263
62. Szabadi E (1992) Fluvoxamine withdrawal syndrome. Br J Psychiat 160: 283-284
63. Thomas D R, Nelson D R, Johnson A M (1987) Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 93: 193-200
64. Tyrer P (1984) Clinical effects of abrupt withdrawal from tricyclic antidepressants and monoamine oxidase inhibitors after long term treatment. J Affect Disord 6: 1-7
65. Young A H, Currie A (1997) Physicians' knowledge of antidepressant withdrawal effects: a survey. J Clin Psychiat 58 (Suppl. 7): 28-30
66. Young A H, Currie A, Ashton C H (1997) Antidepressant withdrawal syndrome. Br J Psychiat 170: 288